|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/03/22 Alignment Healthcare, Inc. 10-K 12/31/21 93:17M Donnelley … Solutions/FA |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 1.62M
2: EX-4.2 Instrument Defining the Rights of Security Holders HTML 54K
3: EX-10.12 Material Contract HTML 146K
4: EX-10.13 Material Contract HTML 136K
5: EX-21.1 Subsidiaries List HTML 31K
6: EX-23.1 Consent of Expert or Counsel HTML 25K
7: EX-31.1 Certification -- §302 - SOA'02 HTML 32K
8: EX-31.2 Certification -- §302 - SOA'02 HTML 32K
9: EX-32.1 Certification -- §906 - SOA'02 HTML 29K
10: EX-32.2 Certification -- §906 - SOA'02 HTML 29K
16: R1 Document and Entity Information HTML 99K
17: R2 Consolidated Balance Sheets HTML 133K
18: R3 Consolidated Balance Sheets (Parenthetical) HTML 47K
19: R4 Consolidated Statements of Operations HTML 91K
20: R5 Consolidated Statements of Stockholders' Equity HTML 93K
21: R6 Consolidated Statements of Stockholders' Equity HTML 29K
(Parenthetical)
22: R7 Consolidated Statements of Cash Flows HTML 131K
23: R8 Organization HTML 42K
24: R9 Summary of Significant Accounting Policies HTML 206K
25: R10 Fair Value HTML 96K
26: R11 Accounts Receivable HTML 57K
27: R12 Property and Equipment HTML 64K
28: R13 Goodwill and Intangible Assets HTML 119K
29: R14 Medical Expenses Payable HTML 170K
30: R15 Long-Term Debt HTML 64K
31: R16 Income Taxes HTML 204K
32: R17 Equity-Based Compensation HTML 323K
33: R18 Regulatory Requirements and Restricted Funds HTML 40K
34: R19 Leases HTML 126K
35: R20 Employee Benefit Plans HTML 32K
36: R21 Commitments and Contingencies HTML 39K
37: R22 Summary of Significant Accounting Policies HTML 260K
(Policies)
38: R23 Summary of Significant Accounting Policies HTML 129K
(Tables)
39: R24 Fair Value (Tables) HTML 90K
40: R25 Accounts Receivable (Tables) HTML 53K
41: R26 Property and Equipment (Tables) HTML 60K
42: R27 Goodwill and Intangible Assets (Tables) HTML 118K
43: R28 Medical Expenses Payable (Tables) HTML 167K
44: R29 Long-Term Debt (Tables) HTML 50K
45: R30 Income Taxes (Tables) HTML 193K
46: R31 Equity-Based Compensation (Tables) HTML 316K
47: R32 Leases (Tables) HTML 115K
48: R33 Organization - Additional Information (Details) HTML 51K
49: R34 Summary of Significant Accounting Policies - HTML 79K
Additional Information (Details)
50: R35 Summary of Significant Accounting Policies - HTML 36K
Schedule of Earned Revenue (Details)
51: R36 Summary of Significant Accounting Policies - HTML 42K
Schedule of Property and Equipment Estimated
Useful Lives (Details)
52: R37 Summary of Significant Accounting Policies - HTML 52K
Schedule of Computation of Basic and Diluted Net
Loss Per Share (Details)
53: R38 Summary of Significant Accounting Policies - HTML 31K
Schedule of Computation of Dilured Net Loss Per
Share (Details)
54: R39 Fair Value - Schedule of Carrying Value and Fair HTML 47K
Value of Financial Instruments (Details)
55: R40 Fair Value - Additional Information (Details) HTML 34K
56: R41 Accounts Receivable - Schedule of Accounts HTML 39K
Receivable (Details)
57: R42 Accounts Receivable - Additional Information HTML 28K
(Details)
58: R43 Property and Equipment - Schedule of Property and HTML 47K
Equipment (Details)
59: R44 Property and Equipment - Additional Information HTML 31K
(Details)
60: R45 Goodwill and Intangible Assets - Schedule of HTML 57K
Intangible Assets (Details)
61: R46 Goodwill and Intangible Assets - Additional HTML 34K
Information (Details)
62: R47 Goodwill and Intangible Assets - Schedule of HTML 42K
Estimated Amortization Expense Related to
Intangible Assets (Details)
63: R48 Medical Expenses Payable - Schedule of Medical HTML 33K
Expenses Payable (Details)
64: R49 Medical Expenses Payable - Components of Change in HTML 51K
Medical Expenses Payable (Details)
65: R50 Medical Expenses Payable - Additional Information HTML 30K
(Details)
66: R51 Medical Expenses Payable - Information About HTML 43K
Incurred and Paid Claims Development (Details)
67: R52 Long-Term Debt - Schedule of Long-Term Debt HTML 42K
Outstanding, Net of Unamortized Debt Issuance
Costs (Details)
68: R53 Long-Term Debt - Additional Information (Details) HTML 72K
69: R54 Income Taxes - Additional Information (Details) HTML 70K
70: R55 Income Taxes - Schedule of Effective Income Tax HTML 76K
Rate Reconciliation (Detail)
71: R56 Income Taxes - Schedule of Components of Income HTML 53K
Tax Expense (Detail)
72: R57 Equity-Based Compensation - Additional Information HTML 113K
(Details)
73: R58 Equity-Based Compensation - Summary of Stock HTML 69K
Option Activity Transactions (Details)
74: R59 Equity-Based Compensation - Schedule of HTML 45K
Weighted-Average Assumptions Used to Determine the
Fair Value of Stock Options Granted (Details)
75: R60 Equity-Based Compensation - Schedule of HTML 37K
Weighted-Average Assumptions Used to Determine the
Fair Value of Stock Options Granted
(Parenthetical) (Details)
76: R61 Equity-Based Compensation - Summary of RSAs HTML 52K
Transactions (Details)
77: R62 Equity-Based Compensation - Summary of RSUs HTML 48K
Transactions (Details)
78: R63 Equity-Based Compensation - Summary of Stock HTML 41K
Appreciation Rights Transactions Converted to RSAs
and Common Stock (Details)
79: R64 Equity-Based Compensation - Equity Based Awards HTML 59K
Converted to RSA and Common Stock (Details)
80: R65 Equity-Based Compensation - Summary Of Unvested HTML 58K
Equity Based Awards Converted To RSA And Common
Stock (Details)
81: R66 Equity-Based Compensation - Schedule of HTML 34K
Equity-based Compensation Expense on Statement of
Operations (Details)
82: R67 Regulatory Requirements and Restricted Funds - HTML 47K
Additional Information (Details)
83: R68 Leases - Additional Information (Details) HTML 66K
84: R69 Leases - Summary of Lease Assets and Liabilities HTML 54K
(Details)
85: R70 Leases - Summary of Maturities of Lease HTML 45K
Liabilities under Operating Leases (Details)
86: R71 Leases - Summary of Maturities of Lease HTML 48K
Liabilities under Finance Leases (Details)
87: R72 Employee Benefit Plans - Additional Information HTML 36K
(Details)
88: R73 Commitments and Contingencies - Additonal HTML 40K
Information (Details)
91: XML IDEA XML File -- Filing Summary XML 168K
89: XML XBRL Instance -- alhc-20211231_htm XML 3.45M
90: EXCEL IDEA Workbook of Financial Reports XLSX 123K
15: EX-101.CAL XBRL Calculations -- alhc-20211231_cal XML 209K
14: EX-101.DEF XBRL Definitions -- alhc-20211231_def XML 749K
11: EX-101.LAB XBRL Labels -- alhc-20211231_lab XML 1.72M
12: EX-101.PRE XBRL Presentations -- alhc-20211231_pre XML 1.29M
13: EX-101.SCH XBRL Schema -- alhc-20211231 XSD 234K
92: JSON XBRL Instance as JSON Data -- MetaLinks 475± 754K
93: ZIP XBRL Zipped Folder -- 0000950170-22-002810-xbrl Zip 1.15M
| EX-4.2 |
Exhibit 4.2
DESCRIPTION OF CAPITAL STOCK
General
Our authorized capital stock consists of 1,000,000,000 shares of common stock, par value $0.001 per share, and 100,000,000 shares of undesignated preferred stock, par value $0.001 per share. As of the February 28, 2022, we had 187,067,046 shares of our common stock outstanding. The following description of our capital stock is intended as a summary only and is qualified in its entirety by reference to our certificate of incorporation and bylaws, which are filed as exhibits to this Annual Report on Form 10-K, and to the applicable provisions of the DGCL.
Common Stock
Dividend Rights. Subject to preferences that may apply to shares of preferred stock outstanding at the time, holders of outstanding shares of common stock are entitled to receive dividends out of assets legally available at the times and in the amounts as our Board may determine from time to time.
Voting Rights. Each outstanding share of common stock is entitled to one vote on all matters submitted to a vote of shareholders. Holders of shares of our common stock have no cumulative voting rights.
Preemptive Rights. Our common stock is not entitled to preemptive or other similar subscription rights to purchase any of our securities.
Conversion or Redemption Rights. Our common stock is neither convertible nor redeemable.
Liquidation Rights. Upon our liquidation, the holders of our common stock will be entitled to receive pro rata our assets that are legally available for distribution, after payment of all debts and other liabilities and subject to the prior rights of any holders of preferred stock then outstanding.
Preferred Stock
Our Board may, without further action by our shareholders, from time to time, direct the issuance of shares of preferred stock in series and may, at the time of issuance, determine the designations, powers, preferences, privileges, and relative participating, optional or special rights as well as the qualifications, limitations or restrictions thereof, including dividend rights, conversion rights, voting rights, terms of redemption and liquidation preferences, any or all of which may be greater than the rights of the common stock. Satisfaction of any dividend preferences of outstanding shares of preferred stock would reduce the amount of funds available for the payment of dividends on shares of our common stock. Holders of shares of preferred stock may be entitled to receive a preference payment in the event of our liquidation before any payment is made to the holders of shares of our common stock. Under certain circumstances, the issuance of shares of preferred stock may render more difficult or tend to discourage a merger, tender offer or proxy contest, the assumption of control by a holder of a large block of our securities or the removal of incumbent management. Upon the affirmative vote of a majority of the total number of directors then in office, our Board, without shareholder approval, may issue shares of preferred stock with voting and conversion rights which could adversely affect the holders of shares of our common stock and the market value of our common stock.
Anti-Takeover Effects of Our Certificate of Incorporation and Our Bylaws
Our certificate of incorporation, bylaws and the DGCL contain provisions, which are summarized in the following paragraphs, that are intended to enhance the likelihood of continuity and stability in the composition of our Board. These provisions are intended to avoid costly takeover battles, reduce our vulnerability to a hostile change of control and enhance the ability of our Board to maximize shareholder value in connection with any unsolicited offer to acquire us. However, these provisions may have an anti-takeover effect and may delay, deter or prevent a merger or acquisition of the Company by means of a tender offer, a proxy contest or other takeover attempt that a shareholder might consider in its best interest, including those attempts that might result in a premium over the prevailing market price for the shares of common stock held by shareholders.
These provisions include:
Classified Board. Our certificate of incorporation provides that our Board will be divided into three classes of directors, with the classes as nearly equal in number as possible, and with the directors serving three-year terms. As a result, approximately one-third of our Board will be elected each year. The classification of directors has the effect of making it more difficult for shareholders to change the composition of our Board. Our certificate of incorporation also provides that, subject to any rights of holders of preferred stock to elect additional directors under specified circumstances, the number of directors will be fixed exclusively pursuant to a resolution adopted by our Board.
Shareholder Action by Written Consent. Our certificate of incorporation precludes shareholder action by written consent at any time when the Lead Sponsors beneficially own, in the aggregate, less than 40% in voting power of our outstanding common stock.
Special Meetings of Shareholders. Our certificate of incorporation and bylaws provide that, except as required by law, special meetings of our shareholders may be called at any time only by or at the direction of our Board or the chairman of our Board provided, however, at any time when the Lead Sponsors beneficially own, in the aggregate, at least 40% of our outstanding common stock, special meetings of our shareholders shall also be called by our Board or the chairman of our Board at the request of either of the Lead Sponsors. Our bylaws prohibit the conduct of any business at a special meeting other than as specified in the notice for such meeting. These provisions may have the effect of deferring, delaying or discouraging hostile takeovers, or changes in control or management of the Company.
Advance Notice Procedures. Our bylaws establish advance-notice procedures with respect to shareholder proposals and the nomination of candidates for election as directors, other than nominations made by or at the direction of our Board or a committee of our Board, and provided, however, that at any time when the Lead Sponsors beneficially own, in the aggregate, at least 40% in voting power of our outstanding common stock, such advance notice procedure will not apply to such Lead Sponsor. Shareholders at an annual meeting will only be able to consider proposals or nominations specified in the notice of meeting or brought before the meeting by or at the direction of our Board or by a shareholder who was a shareholder of record on the record date for the meeting, who is entitled to vote at the meeting and who has given our Secretary timely written notice, in proper form, of the shareholder’s intention to bring that business before the meeting. Although the bylaws do not give our Board the power to approve or disapprove shareholder nominations of candidates or proposals regarding other business to be conducted at a special or annual meeting, the bylaws may have the effect of precluding the conduct of certain business at a meeting if the proper procedures are not followed or may discourage or deter a potential acquirer from conducting a solicitation of proxies to elect its own slate of directors or otherwise attempting to obtain control of the Company. These provisions do not apply to nominations by the Lead Sponsors pursuant to the Stockholders Agreement.
Removal of Directors; Vacancies. Our certificate of incorporation provides all directors may only be removed for cause, and only by the affirmative vote of holders of at least 66 2/3% in voting power of all the then- outstanding shares of stock of the Company entitled to vote thereon, voting together as a single class. In addition, our certificate of incorporation also provides that, subject to the rights granted to one or more series of preferred stock then outstanding, any newly created directorship on our Board that results from an increase in the number of directors and any vacancy occurring on our Board may only be filled by a majority of the directors then in office, even if less than a quorum, or by a sole remaining director (and not by the shareholders).
Supermajority Approval Requirements
Our certificate of incorporation and bylaws provide that our Board is expressly authorized to make, alter, amend, change, add to, rescind or repeal, in whole or in part, our bylaws without a shareholder vote in any matter not inconsistent with the laws of the State of Delaware and our certificate of incorporation. Any amendment, alteration, rescission or repeal of our bylaws by our shareholders requires the affirmative vote of the holders of at least 66 2/3% in voting power of all the then-outstanding shares of stock of the Company entitled to vote thereon, voting together as a single class.
The DGCL provides generally that the affirmative vote of a majority of the outstanding shares entitled to vote thereon, voting together as a single class, is required to amend a corporation’s certificate of incorporation, unless the certificate of incorporation requires a greater percentage.
Our certificate of incorporation provides that the following provisions in our certificate of incorporation may be amended, altered, repealed or rescinded only by the affirmative vote of the holders of at least 66 2/3% in voting power of all the then-outstanding shares of stock of the Company entitled to vote thereon, voting together as a single class:
The combination of the classification of our Board, the lack of cumulative voting and the supermajority voting requirements make it more difficult for our existing shareholders to replace our Board as well as for another party to obtain control of us by replacing our Board. Because our Board has the power to retain and discharge our officers, these provisions could also make it more difficult for existing shareholders or another party to effect a change in management.
Authorized but Unissued Shares
Our authorized but unissued shares of common stock and preferred stock are available for future issuance without shareholder approval, subject to stock exchange rules. These additional shares may be utilized for a variety of corporate purposes, including future public offerings to raise additional capital, corporate acquisitions and employee benefit plans. One of the effects of the existence of authorized but unissued common stock or preferred stock may be to enable our Board to issue shares to persons friendly to current management, which issuance could render more difficult or discourage an attempt to obtain control of the Company by means of a merger, tender offer, proxy contest or otherwise, and thereby protect the continuity of our management and possibly deprive our shareholders of opportunities to sell their shares of common stock at prices higher than prevailing market prices.
Business Combinations
We are not be subject to the provisions of Section 203 of the DGCL. In general, Section 203 prohibits a publicly held Delaware corporation from engaging in a “business combination” with an “interested shareholder” for a three-year period following the time that the person becomes an interested shareholder, unless the business combination is approved in a prescribed manner. A “business combination” includes, among other things, a merger, asset or stock sale or other transaction resulting in a financial benefit to the interested shareholder. An “interested shareholder” is a person who, together with affiliates and associates, owns, or did own within three years prior to the determination of interested shareholder status, 15% or more of the corporation’s voting stock.
Under Section 203, a business combination between a corporation and an interested shareholder is prohibited unless it satisfies one of the following conditions: (1) before the shareholder became an interested shareholder, the board of directors approved either the business combination or the transaction which resulted in the shareholder becoming an interested shareholder; (2) upon consummation of the transaction which resulted in the shareholder becoming an interested shareholder, the interested shareholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding, shares owned by persons who are directors and also officers, and employee stock plans, in some instances; or (3) at or after the time the shareholder became an interested shareholder, the business combination was approved by the board of directors and authorized at an annual or special meeting of the shareholders by the affirmative vote of at least two-thirds of the outstanding voting stock which is not owned by the interested shareholder.
A Delaware corporation may “opt out” of these provisions with an express provision in its original certificate of incorporation or an express provision in its certificate of incorporation or bylaws resulting from a shareholders’ amendment approved by at least a majority of the outstanding voting shares.
We have opted out of Section 203; however, our certificate of incorporation contains similar provisions providing that we may not engage in certain “business combinations” with any “interested shareholder” for a three-year period following the time that the shareholder became an interested shareholder, unless:
Under certain circumstances, this provision makes it more difficult for a person who would be an “interested shareholder” to effect various business combinations with the Company for a three-year period. This provision may encourage companies interested in acquiring the Company to negotiate in advance with our Board because the shareholder approval requirement would be avoided if our Board approves either the business combination or the transaction which results in the shareholder becoming an interested shareholder. These provisions also may have the effect of preventing changes in our Board and may make it more difficult to accomplish transactions which shareholders may otherwise deem to be in their best interests.
Our certificate of incorporation provides that the Lead Sponsors, and any of their direct or indirect transferees and any group as to which such persons are a party, do not constitute “interested shareholders” for purposes of this provision.
Dissenters’ Rights of Appraisal and Payment
Under the DGCL, with certain exceptions, our shareholders have appraisal rights in connection with a merger or consolidation of us. Pursuant to the DGCL, shareholders who properly request and perfect appraisal rights in connection with such merger or consolidation will have the right to receive payment of the fair value of their shares as determined by the Delaware Court of Chancery.
Shareholders’ Derivative Actions
Under the DGCL, any of our shareholders may bring an action in our name to procure a judgment in our favor, also known as a derivative action, provided that the shareholder bringing the action is a holder of our shares at the time of the transaction to which the action relates or such shareholder’s stock thereafter devolved by operation of law.
Exclusive Forum
Our certificate of incorporation provides that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if the Court of Chancery does not have jurisdiction, the United States District Court for the District of Delaware) will be the sole and exclusive forum for (1) any derivative action or proceeding brought on our behalf, (2) any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers or other employees to us or our shareholders, (3) any action asserting a claim against the Company or any director or officer of the Company arising pursuant to any provision of the DGCL, our certificate of incorporation or our bylaws or (4) any other action asserting a claim against the Company or any director or officer of the Company that is governed by the internal affairs doctrine; provided that for the avoidance of doubt, the forum selection provision that identifies the Court of Chancery of the State of Delaware as the exclusive forum for certain litigation, including any “derivative action”, will not apply to suits to enforce a duty or liability created by the Securities Act, the Exchange Act or any other claim for which there is exclusive federal or concurrent federal and state jurisdiction. Additionally, unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States of America shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. Although we believe these exclusive forum provisions benefit us by providing increased consistency in the application of Delaware law and federal securities laws in the types of lawsuits to which each applies, the exclusive forum provisions may limit a stockholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or any of our directors, officers or stockholders, which may discourage lawsuits with respect to such claims. Our stockholders are not deemed to have waived our compliance with the federal securities laws and the rules and regulations thereunder as a result of our exclusive forum provisions. Further, in the event a court finds any such exclusive forum provision contained in our certificate of incorporation to be unenforceable or inapplicable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could harm our business, operating results and financial condition. Any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock will be deemed to have notice of and to have consented to the provisions of our certificate of incorporation described above. Although we believe these provisions benefit us by providing increased consistency in the application of Delaware law for the specified types of actions and proceedings, the provisions may have the effect of discouraging lawsuits against us or our directors and officers.
Conflicts of Interest
Delaware law permits corporations to adopt provisions renouncing any interest or expectancy in certain opportunities that are presented to the corporation or its officers, directors or shareholders. Our certificate of incorporation, to the maximum extent permitted from time to time by Delaware law, renounces any interest or expectancy that we have in, or right to be offered an opportunity to participate in, specified business opportunities that are from time to time presented to certain of our officers, directors or shareholders or their respective affiliates, other than those officers, directors, shareholders or affiliates who are our or our subsidiaries’ employees. Our certificate of incorporation provides that, to the fullest extent permitted by law, none of Lead Sponsors or any director who is not employed by us (including any non-employee director who serves as one of our officers in both his director and officer capacities) or his or her affiliates will have any duty to refrain from (1) engaging in a corporate opportunity in the same or similar lines of business in which we or our affiliates now engage or propose to engage or (2) otherwise competing with us or our affiliates. In addition, to the fullest extent permitted by law, in the event that Lead Sponsors or any non-employee director acquires knowledge of a potential transaction or other business opportunity which may be a corporate opportunity for itself or himself or its or his affiliates or for us or our affiliates, such person will have no duty to communicate or offer such transaction or business opportunity to us or any of our affiliates and they may take any such opportunity for themselves or offer it to another person or entity. Our certificate of incorporation does not renounce our interest in any business opportunity that is expressly offered to a non-employee director solely in his or her capacity as a director or officer of the Company. To the fullest extent permitted by law, no business opportunity will be deemed to be a potential corporate opportunity for us unless we would be permitted to undertake the opportunity under our certificate of incorporation, we have sufficient financial resources to undertake the opportunity, and the opportunity would be in line with our business.
Limitations on Liability and Indemnification of Officers and Directors
The DGCL authorizes corporations to limit or eliminate the personal liability of directors to corporations and their shareholders for monetary damages for breaches of directors’ fiduciary duties, subject to certain exceptions.
Our certificate of incorporation includes a provision that eliminates the personal liability of directors for monetary damages for any breach of fiduciary duty as a director, except to the extent such exemption from liability or limitation thereof is not permitted under the DGCL. The effect of these provisions is to eliminate the rights of us and our shareholders, through shareholders’ derivative suits on our behalf, to recover monetary damages from a director for breach of fiduciary duty as a director, including breaches resulting from grossly negligent behavior. However, exculpation will not apply to any director if the director has acted in bad faith, knowingly or intentionally violated the law, authorized illegal dividends or redemptions or derived an improper benefit from his or her actions as a director.
Our bylaws provide that we must indemnify and advance expenses to our directors and officers to the fullest extent authorized by the DGCL. We also are expressly authorized to carry directors’ and officers’ liability insurance providing indemnification for our directors, officers and certain employees for some liabilities. We believe that these indemnification and advancement provisions and insurance are useful to attract and retain qualified directors and officers.
The limitation of liability, indemnification and advancement provisions that are included in our certificate of incorporation and bylaws may discourage shareholders from bringing a lawsuit against directors for breaches of their fiduciary duty. These provisions also may have the effect of reducing the likelihood of derivative litigation against directors and officers, even though such an action, if successful, might otherwise benefit us and our shareholders. In addition, your investment may be adversely affected to the extent we pay the costs of settlement and damage awards against directors and officers pursuant to these indemnification provisions.
There is currently no pending material litigation or proceeding involving any of our directors, officers or employees for which indemnification is sought.
Transfer Agent and Registrar
The transfer agent and registrar for our common stock is American Stock Transfer & Trust Company, LLC. The transfer agent’s address is 6201 15th Avenue, Brooklyn, New York, 11219 and its phone number is (718) 921-8200.
Listing
Our common stock is listed on Nasdaq under the symbol “ALHC”.
| This ‘10-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 3/3/22 | 8-K | ||
| 2/28/22 | ||||
| For Period end: | 12/31/21 | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/27/24 Alignment Healthcare, Inc. 10-K 12/31/23 99:15M Donnelley … Solutions/FA 2/28/23 Alignment Healthcare, Inc. 10-K 12/31/22 97:18M Donnelley … Solutions/FA 9/19/22 Alignment Healthcare, Inc. 424B7 2:498K Donnelley … Solutions/FA 9/15/22 Alignment Healthcare, Inc. 424B7 1:465K Donnelley … Solutions/FA 9/15/22 Alignment Healthcare, Inc. S-3ASR 9/15/22 5:1M Donnelley … Solutions/FA |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 5/17/21 Alignment Healthcare, Inc. 10-Q 3/31/21 80:8.4M Donnelley … Solutions/FA 3/30/21 Alignment Healthcare, Inc. 8-K:1,3,5,8 3/25/21 8:869K Donnelley … Solutions/FA 3/23/21 Alignment Healthcare, Inc. S-1/A 14:7.3M Donnelley … Solutions/FA 3/03/21 Alignment Healthcare, Inc. S-1 10:7.1M Donnelley … Solutions/FA |